Page results
-
One of the FOIA Code of Practice requirements is for public authorities to publish more information about their performance in handling FOIA requests.
-
Exhibition co-curated by Healthcare Arts Collective and UCLH Arts and Heritage 25th August - 20th October 2021, UCH Street Gallery, 235 Euston Road
-
Matthew Fielden and Lillyanne Tran volunteer in the cognitive disorders outpatients’ clinic at the National Hospital for Neurology and Neurosurgery.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
A large trial at UCLH and UCL will investigate whether a drug currently in use to treat respiratory conditions can slow the progress of Parkinson’s disease.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
A UCLH/UCL clinical trial of a personalised therapy for blood cancer has been expanded, meaning new groups of patients with a wider range of blood cancers are now receiving the treatment.
-
A major new review published in BJU International explores additional treatments and lifestyle measures for men with early prostate cancer who are managed with active surveillance, as well as monitoring tools that may help guide care.
File results
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm